Skip to main content
. 2023 Jan 31;7(10):2008–2017. doi: 10.1182/bloodadvances.2022009389

Figure 1.

Figure 1.

EFS and OS in patients with or without high BCL2/MYC coexpression. Overall EFS and OS in patients with or without high BCL2/MYC coexpression determined by RNA-seq in the placebo plus R-CHOP (A,B) and ibrutinib plus R-CHOP (C,D) arms.